Taurolidine
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 9.6-34.2 microM for several cancer cell lines
Taurolidine is a synthetic taurine analog with antimicrobial and anti-neoplastic actions.
Taurine, a conditionally-essential amino acid, is not utilized in protein synthesis, but is found free or in simple peptides. Taurine has been shown to be essential in mammalian development. In vitro studies have demonstrated that low levels of taurine are associated with various pathological lesions.
In vitro: Previous study found that in selected human and murine tumor cell lines, a 3-day exposure to taurolidine could inhibit the growth of all of the cell lines. Further mechanistic study showed that in NIH-3T3 murine fibroblasts and the PA-1 and SKOV-3 human ovarian tumor cells, a 48-h exposure to taurolidine had little effect on cell cycle distribution in PA-1 and SKOV-3 cells but greatly increased the appearance of DNA debris, an effect consistent with an induction of apoptosis. In contrast, in NIH-3T3 cells, taurolidine exposure did not increase DNA debris in the sub-G(0)/G(1) region [1].
In vivo: Animal study found that the i.v. administration of 2% taurolidine and 3% taurolidine as well the i.p. application of 2% taurolidine could decrease the development of advanced i.p. tumor lesions. No changes of differential blood count nor relevant animal weight changes resulted. Moreover, taurolidine did not impair the liver tissue, kidneys, SVC, and leucopoiesis. The intravenous therapy of 2% taurolidine was found to be safe and anti-tumorigenic in advanced local tumor growth in rats [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Calabresi, P. ,Goulette, F.A. and Darnowski, J.W. Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Research 61(18), 6816-6821 (2001).
[2] Braumann C, Stuhldreier B, Bobrich E, Menenakos C, Rogalla S, Jacobi CA. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res. 2005 Nov;129(1):129-35.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 284.4 |
Cas No. | 19388-87-5 |
Formula | C7H16N4O4S2 |
Solubility | insoluble in EtOH; ≥2.64 mg/mL in H2O with gentle warming and ultrasonic; ≥52.8 mg/mL in DMSO |
Chemical Name | 4,4'-methylenebis(tetrahydro-1,2H,4-thiadiazine) 1,1,1',1'-tetraoxide |
SDF | Download SDF |
Canonical SMILES | O=S1(CCN(CN2CNS(CC2)(=O)=O)CN1)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
PA-1 and SKOV-3肿瘤细胞系 |
溶解方法 |
在DMSO中的溶解度≤10mg/ml。为了获得更高的浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
反应条件 |
25 μM, 50 μM, 100 μM |
应用 |
研究结果表明,在PA-1和SKOV-3肿瘤细胞系中,24小时接触taurolidine会引起膜联结合蛋白-V显著的浓度依赖性增加。相反,在NIH-3T3细胞中,taurolidine暴露导致抗体结合率无显着增加(〜5%)。 |
动物实验 [1]: | |
动物模型 |
人卵巢肿瘤异种移植物的裸鼠 |
剂量 |
5 to 30 mg/小鼠,腹腔注射给药,持续3天 |
应用 |
研究结果表明,低于15 mg /小鼠/天(〜650 mg / kg /天)的剂量具有良好的耐受性。这些剂量方案导致的体重减轻≤7%,并且在注射方案后7天内体重恢复到注射前水平。使用20 mg /小鼠/天或更大剂量的方案,观察到更明显的毒性。使用20、25或30 mg /小鼠的方案的最低体重减轻分别为-12%,-16%和-25%。此外,以上taurolidine剂量方案分别导致13%,43%和100%的死亡率。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同,这是由实验系统的误差引起的,属于正常现象。 |
References: [1]. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res. 2001 Sep15;61(18):6816-21. PubMed PMID: 11559556. |
质量控制和MSDS
- 批次: